AI biomanufacturing company Tianwu Technology recently announced the completion of a Series A+ funding round exceeding 200 million yuan. This round was jointly led by PetroChina's Kunlun Capital, existing investor Yonghua Investment, and the Shanghai Future Industry Fund. Additional participants included institutions such as SDIC招商, New Supply and Marketing Fund, Farmer Kai, and Futeng Capital. Existing shareholders, including Qiming Venture Partners, Jinshajiang United Capital's Runpu Medical Fund, and Herbal Capital, continued to increase their investments.
Tianwu Technology, founded in 2021, is an AI-driven, full-stack protein research and development platform company. Established by a team from Shanghai Jiao Tong University, it was one of the earliest enterprises in China to focus on developing large AI models for proteins. The company has currently built a massive protein sequence dataset and label library named Venus, which aggregates nearly 10 billion protein sequences, including 6.5 billion entries tagged with environmental factors such as temperature, pressure, and pH levels. Building on this foundation, Tianwu has created the general-purpose large protein design model AIACCLBIO®, enabling precise, industry-demand-oriented design of functional proteins.
The company's objective is to fully integrate AI into industrial application scenarios, facilitating the faster and more efficient development of various bioproducts based on proteins as fundamental components. These applications span areas including innovative pharmaceuticals, health and wellness, agriculture, functional foods, and bio-based materials.
Comments